AbCellera Biologics Inc. (NASDAQ:ABCL) CEO Carl L. G. Hansen sold 6,000,000 shares of the stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $24.13, for a total transaction of $144,780,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of NASDAQ:ABCL opened at $24.84 on Friday. The stock has a 50 day moving average of $28.99. The firm has a market cap of $6.73 billion and a price-to-earnings ratio of 55.20. AbCellera Biologics Inc. has a twelve month low of $23.20 and a twelve month high of $71.91.
AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Wednesday, May 12th. The company reported $0.37 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.37. The company had revenue of $202.74 million during the quarter, compared to analyst estimates of $199.43 million. On average, sell-side analysts expect that AbCellera Biologics Inc. will post 0.44 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Evoke Wealth LLC purchased a new stake in shares of AbCellera Biologics in the 1st quarter valued at approximately $27,000. Lumina Fund Management LLC acquired a new stake in AbCellera Biologics during the 1st quarter valued at $102,000. UBS Group AG lifted its holdings in shares of AbCellera Biologics by 38,262.5% in the first quarter. UBS Group AG now owns 3,069 shares of the company’s stock valued at $104,000 after purchasing an additional 3,061 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in shares of AbCellera Biologics in the fourth quarter worth $212,000. Finally, Stifel Financial Corp purchased a new position in shares of AbCellera Biologics during the first quarter valued at $247,000. 26.09% of the stock is currently owned by institutional investors and hedge funds.
About AbCellera Biologics
AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract.
Read More: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.